Across TCGA pan-cancer cohorts, FAM221A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM221A data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher FAM221A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM221A expression acts as an unfavorable survival marker.

KIRP, BRCA, and SARC are the cancer types where FAM221A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.141	0.904	<.001	36	view →
BRCA	OS	Median	All	0.595	0.924	<.001	29	view →
SARC	OS	Median	All	0.178	0.745	.008	6	view →
SKCM	DFS	Median	II,III,IV	0.192	0.707	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: FAM221A tumor-vs-normal RNA expression · all FAM221A data types